12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RXI-109: Completed Phase I enrollment

RXi completed enrollment in a double-blind, placebo-controlled, dose-escalation Phase I trial evaluating intradermal injections of 2.5-7.5 mg RXI-109 given 3 times over 2...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >